Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S.-China Hybrid Ascletis Helps Forge Stronger Ties Between China And North Carolina

This article was originally published in PharmAsia News

Executive Summary

U.S.-China hybrid Ascletis Inc. has reinforced ties between China and the U.S. under a memorandum of understanding signed July 16 with the Hangzhou Hi-Tech Industry Development Zone in Zhejiang Province, China, and The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina

You may also be interested in...



Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.

Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing

HANGZHOU, China - U.S.-China hybrid Ascletis Inc. is putting some of its $100 million Series A funding to immediate use, breaking ground Oct. 20 on a facility in Zhenjiang Province that will house its China headquarters and R&D center

Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing

HANGZHOU, China - U.S.-China hybrid Ascletis Inc. is putting some of its $100 million Series A funding to immediate use, breaking ground Oct. 20 on a facility in Zhenjiang Province that will house its China headquarters and R&D center

Related Content

UsernamePublicRestriction

Register

SC078586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel